Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pharmacia
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Concurrent Medication:
Allowed:
Zidovudine (AZT).
Didanosine (ddI).
Patients must have the following:
Diagnosis of AIDS as defined by the CDC.
Blood cultures positive for Mycobacterium avium complex or for acid-fast bacilli (AFB).
Provide written informed consent.
Prior Medication:
Allowed:
If receiving zidovudine (AZT) or ddI must be taking the medication for at least 4 weeks prior to study entry.
Required:
Antipneumocystis prophylactic therapy for at least 4 weeks prior to study entry.
You may not be if
Co-existing Condition:
Patients with the following conditions or symptoms are excluded:
Known hypersensitivity to any of the study drugs.
Concurrent Medication:
Excluded:
Other therapy for mycobacterial disease.
Patients with the following are excluded:
Known hypersensitivity to any of the study drugs.
Prior Medication:
Excluded within 4 weeks:
Therapy for mycobacterial disease.
Antiretroviral drugs, other than zidovudine (AZT) or ddI.
Investigational drugs, other than ddI.
Clareo Health | A Double-Blind Randomized Clinical Trial of a Rifabutin Regimen in the Treatment of Mycobacterium-Avium Complex (MAC) Bacteremia in Patients With AIDS
